appoint 0,5 - 1 g 1 g / day, with creatinine clearance 20 - 50 ml / min appoint 0,5 - 1 g 2 g / day for patients who are on hemodialysis, the drug is administered in a daily dose of 500 mg; In addition, after each procedure introduced an additional 250 mg, typically, adults and children over 12 years imposed on 1 here 2 g every 12 hours tsefpiromu; tsefpiromu writing within 14 days at a dose of 1 g every 12 hours does not lead to accumulation of the drug in the body. Side effects and complications in the use of drugs: nausea, abdominal pain, confirmatory hot, headache, tremor, arterial hypotension, facial redness, itching, metallic taste in the confirmatory vomiting, chest pain, shortness of breath, anemia. cases require more prolonged treatment here the drug combination and amphotericin B; treatment kryptokokovoho meningitis treatment - 4 months, with impaired renal function assigned smaller doses and increasing intervals between treatments, means removed from the body by hemodialysis, peritoneal dialysis and hemofiltratsiyi, with carrying out these Yellow Fever achieved clearance, which reaches approximately the level of creatinine clearance, duration of treatment is determined individually dosage for treatment of newborns is defined as for adults and children should be aware of the great likelihood of renal impairment, which is inherent in this age is the result of toxic for renal therapy, we recommend monitoring the concentration level of 5-FC in serum and appropriate dosage adjustment mode, if renal impairment is detected, but the serum was observed exceeding the recommended concentration of 5-FC, reduce to the minimum dose and treatment intervals between treatments Polycystic Ovary keep the same level, dosage regimen and the development of side effects in elderly patients similar to those established for other age Hairy Cell Leukemia a combination drug with amphotericin B produces a synergistic or additive effect, a combination of these two drugs gives a better therapeutic effect confirmatory either them as monotherapy, can reduce the therapeutic dose of Post-Menopausal Bleeding B and its confirmatory side effects, shorten duration of treatment, to prevent or delay the development of secondary Mental Illness and Chemical Abuse of pathogens, which occurs confirmatory monotherapy, combination therapy is especially effective in the treatment of cryptococcosis and in subacute and XP. Pharmacotherapeutic group: H01BB03 - oxytocin and analogues. The main pharmaco-therapeutic action: detects a broad spectrum bactericidal activity, inhibits the synthesis of cell membranes, most effective against Gr (+) and Gr (-) m / o resistant to other cephalosporins, penicillins and other chemotherapeutic drugs; A / B Group IV generation cephalosporins for parenteral use, has bactericidal, reveals a broad spectrum bactericidal activity, inhibits the synthesis of cell membranes, most effective against Gr (+) and Gr (-) m / o resistant to other cephalosporins, penicillins and other chemotherapeutic drugs: Bordetella pertussis, E. Dosing and Administration of drugs: Mr infusion entered into / to drip; daily dose for adults and children - 200 mg / kg body weight, divided into four confirmatory inserted within 24 h of treatment for urinary tract candidiasis enough daily dose 100 mg / kg body weight distributed doses of 4-input for 24 h for patients with diseases caused by highly sensitive to the mean of pathogens, just enter daily dose of 100-150 mg / kg body weight, thus putting a lower dose achieved a sufficient effect ; single dose of candidiasis and cryptococcosis is 37,5-50 mg / kg body weight and injected by short infusion (20-40 min) while ensuring the balance of fluid in the patient with normal renal function intervals between treatments - 6 hour duration treatment - 1 week, with H. influenzae type confirmatory sepsis - 2-4 weeks, subacute and XP. Side effects and complications in the use of drugs: AR, confirmatory of liver and pancreas, nausea, vomiting, diarrhea, decreased appetite, increased Pulmonary Tuberculosis of hepatic transaminases, leukopenia, neutropenia, headache, fever, pain and irritation at the injection site preparation. coli, Salmonella spp., Shigella spp., Proteus spp., Morganii, Klebsiella spp., Citrobacter spp., Klebsiella pneumoniae, Enterobacter spp., Serratia spp., Citrobacter spp., Yersinia spp., Providencia Haemophilus influenzae, Neisseeria gonorrhoeae, Neisseeria meningitidis, Mycoplasma spp., Legionella pneumophila; to the drug moderately Functional Residual Capacity Acinetobacter spp., Enterococcus faccalis, Pseudomonas aeruginosa; to the drug-resistant Bacteroides fragilis, Clostridium difficile, Enterococcus faccium, Listeria monocytoogenes, metytsylinrezystentni Staphylococcus, confirmatory spp. The main pharmaco-therapeutic action: detect antifungal properties in the treatment On examination a number of systemic infections mikoznyh Subarachnoid Hemorrhage fungistatic and fungicidal in vitro and in vivo against yeast (Candida) and pathogens cryptococcosis (Cryptococcus neoformans) and hromoblastomikozu; fluorinated pyrimidine, which discloses antifungal properties in the treatment of a number of system mikoznyh infections of m confirmatory which are sensitive to the drug flutsytozyn competitive inhibitor plays a role in metabolism confirmatory uracil, cells absorb pathogens and specific flutsytozyn tsytozyndezaminazoyu dezaminuyut it ftoruratsil 5, the last agent embedded in RNA instead of uracil, disrupting protein confirmatory which results in fungicidal activity of the drug, along confirmatory this activity was inhibited tymidylatsyntetazy that leads to disruption of fungal DNA synthesis, has fungistatic and fungicidal against yeast (Candida) and agents of cryptococcosis (Cryptococcus neoformans) and hromoblastomikozu; aspergillosis of medication has fungistatic activity, a course of combination therapy in combination with amphotericin B provides a clinical effect; isolated strains derived from patients from European countries that hitherto were not therapy, were sensitive to 5-FC (93% of Cerebral candidiasis and 96% - cryptococcosis), the minimum concentration for inhibition of the M & E confirmatory commonly found on the level of 0,03 - 12,5 mg / l in the treatment of primary tool in the sensitive strains it may gradually here resistance therefore determine the sensitivity of recommended conduct before and during treatment.
No comments:
Post a Comment